Drug Trial Radar · NCT00612742
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,656
Actual
Start
Jan 2008
Primary completion
Oct 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- BioSante PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, adaptive design, multi-center study of the long-term cardiovascular and breast safety of LibiGel in the treatment of HSDD in postmenopausal women with at least two points of cardiovascular risk and clinical diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
Conditions
- Hypoactive Sexual Desire Disorder
Interventions
testosterone gelDrug
once daily transdermal testosterone gel, 300 mcg
placebo gelDrug
once daily transdermal placebo gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of adjudicated, predefined cardiovascular events in LibiGel-treated subjects compared to that of placebo-treated subjects.Time frame: 2011 primary outcome analysis for NDA submission
Locations
149 sites in 2 countries. Site status is shown where the registry gives one.
BioSante Site #215
Birmingham, Alabama
BioSante Site 185
Birmingham, Alabama
BioSante Site 095
Hoover, Alabama
BioSante Site #014
Huntsville, Alabama
BioSante Site 196
Huntsville, Alabama
BioSante Site 146
Mobile, Alabama
BioSante Site 171
Chandler, Arizona
BioSante Site 145
Glendale, Arizona
BioSante Site 027
Glendale, Arizona
BioSante Site 121
Phoenix, Arizona
BioSante Site 137
Tucson, Arizona
BioSante Site 040
Tucson, Arizona
BioSante Site 052
Hot Springs, Arkansas
BioSante Site 100
Jonesboro, Arkansas
BioSante Site #060
Little Rock, Arkansas
BioSante Site 155
Little Rock, Arkansas
BioSante Site 011
Los Angeles, California
BioSante Site 094
Palm Springs, California
BioSante Site 043
Roseville, California
BioSante Site 162
Sacramento, California
BioSante Site 025
Sacramento, California
BioSante Site 112
San Diego, California
BioSante Site 008
San Diego, California
BioSante Site #070
San Diego, California
BioSante Site 205
San Diego, California
BioSante Site #192
San Diego, California
BioSante Site 159
Walnut Creek, California
BioSante Site 007
Denver, Colorado
BioSante Site 216
Denver, Colorado
BioSante Site 026
Lakewood, Colorado
BioSante Site 166
Farmington, Connecticut
BioSante Site 103
Hartford, Connecticut
BioSante Site 132
New Britain, Connecticut
BioSante Site 151
New London, Connecticut
BioSante Site 036
Ridgefield, Connecticut
BioSante Site 013
Washington D.C., District of Columbia
BioSante Site 118
Aventura, Florida
BioSante Site 139
Crystal River, Florida
BioSante Site 143
Jacksonville, Florida
BioSante Site 180
Melbourne, Florida
Showing 40 of 149 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.